{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:48:03Z","timestamp":1774583283168,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of pre-existing hypertension on outcomes in patients with the novel corona virus (SARS-CoV-2) remains controversial. To address this, we examined the impact of pre-existing hypertension and its treatment on in-hospital mortality in patients admitted to hospital with Covid-19. Using the CAPACITY-COVID patient registry we examined the impact of pre-existing hypertension and guideline-recommended treatments for hypertension on in-hospital mortality in unadjusted and multi-variate-adjusted analyses using logistic regression. Data from 9197 hospitalised patients with Covid-19 (median age 69 [IQR 57\u201378] years, 60.6% male, <jats:italic>n<\/jats:italic>\u2009=\u20095573) was analysed. Of these, 48.3% (<jats:italic>n<\/jats:italic>\u2009=\u20094443) had documented pre-existing hypertension. Patients with pre-existing hypertension were older (73 vs. 62 years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and had twice the occurrence of any cardiac disease (49.3 vs. 21.8%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) when compared to patients without hypertension. The most documented class of anti-hypertensive drugs were angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi) (<jats:italic>n<\/jats:italic>\u2009=\u20092499, 27.2%). In-hospital mortality occurred in (<jats:italic>n<\/jats:italic>\u2009=\u20092020, 22.0%), with more deaths occurring in those with pre-existing hypertension (26.0 vs. 18.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Pre-existing hypertension was associated with in-hospital mortality in unadjusted analyses (OR 1.57, 95% CI 1.42,1.74), no significant association was found following multivariable adjustment for age and other hypertension-related covariates (OR 0.97, 95% CI 0.87,1.10). Use of ACEi or ARB tended to have a protective effect for in-hospital mortality in fully adjusted models (OR 0.88, 95% CI 0.78,0.99). After appropriate adjustment for confounding, pre-existing hypertension, or treatment for hypertension, does not independently confer an increased risk of in-hospital mortality patients hospitalized with Covid-19.<\/jats:p>","DOI":"10.1038\/s41440-022-00893-5","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T20:31:55Z","timestamp":1648585915000},"page":"834-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19"],"prefix":"10.1038","volume":"45","author":[{"given":"Ewan","family":"McFarlane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijke","family":"Linschoten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawid","family":"Jedrzejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on Behalf of the CAPACITY-COVID Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"893_CR1","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","volume":"41","author":"C Gao","year":"2020","unstructured":"Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41:2058\u201366.","journal-title":"Eur Heart J"},{"key":"893_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jch.14146","volume":"23","author":"Y Sun","year":"2021","unstructured":"Sun Y, Guan X, Jia L, Xing N, Cheng L, Liu B, et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J Clin Hypertens (Greenwich). 2021;23:218\u201331.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"893_CR3","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.","journal-title":"Lancet Respir Med"},{"key":"893_CR4","unstructured":"Kanwal A, Agarwala A, Warsinger-Martin L, Handberg EM COVID 19 and Hypertension: What we know and what we don\u2019t know: ACC; 2020 [Available from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/07\/06\/08\/15\/covid-19-and-hypertension."},{"key":"893_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/jch.13917","volume":"22","author":"K Kario","year":"2020","unstructured":"Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, et al. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2020;22:1109\u201319.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"893_CR6","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl J Med. 2020;382:1653\u20139.","journal-title":"N. Engl J Med"},{"key":"893_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41440-020-0515-0","volume":"43","author":"S Shibata","year":"2020","unstructured":"Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43:1028\u201346.","journal-title":"Hypertens Res"},{"key":"893_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91\u20135.","journal-title":"Int J Infect Dis"},{"key":"893_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/heartjnl-2020-317901","volume":"107","author":"S Bae","year":"2021","unstructured":"Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart 2021;107:373\u201380.","journal-title":"Heart"},{"key":"893_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020;323:2052\u20139.","journal-title":"JAMA"},{"key":"893_CR11","doi-asserted-by":"crossref","unstructured":"Khawaja SA, Mohan P, Jabbour R, Bampouri T, Bowsher G, Hassan AMM, et al. COVID-19 and its impact on the cardiovascular system. Open Heart. 2021;8:e001472.","DOI":"10.1136\/openhrt-2020-001472"},{"key":"893_CR12","doi-asserted-by":"publisher","first-page":"e047561","DOI":"10.1136\/bmjopen-2020-047561","volume":"11","author":"A Basu","year":"2021","unstructured":"Basu A, Agwu JC, Barlow N, Lee B. Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: a retrospective cohort study. BMJ Open. 2021;11:e047561.","journal-title":"BMJ Open"},{"key":"893_CR13","doi-asserted-by":"publisher","first-page":"e044640","DOI":"10.1136\/bmjopen-2020-044640","volume":"11","author":"BG Pijls","year":"2021","unstructured":"Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11:e044640.","journal-title":"BMJ Open"},{"key":"893_CR14","doi-asserted-by":"publisher","first-page":"e0254066","DOI":"10.1371\/journal.pone.0254066","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021;16:e0254066.","journal-title":"PLoS One"},{"key":"893_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430\u20136.","journal-title":"Nature"},{"key":"893_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"893_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/HYPERTENSIONAHA.120.15289","volume":"76","author":"W Pan","year":"2020","unstructured":"Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, et al. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. Hypertension. 2020;76:732\u201341.","journal-title":"Hypertension."},{"key":"893_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345\u201355.","journal-title":"JAMA Intern Med"},{"key":"893_CR19","doi-asserted-by":"publisher","first-page":"639222","DOI":"10.3389\/fcvm.2021.639222","volume":"8","author":"M Tadic","year":"2021","unstructured":"Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: ongoing controversies. Front Cardiovasc Med. 2021;8:639222.","journal-title":"Front Cardiovasc Med"},{"key":"893_CR20","unstructured":"WHO. Hypertension and COVID-19: Scientific Brief. 2021."},{"key":"893_CR21","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/eurheartj\/ehaa280","volume":"41","author":"M Linschoten","year":"2020","unstructured":"Linschoten M, Asselbergs FW. CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart J 2020;41:1795\u20136.","journal-title":"Eur Heart J"},{"key":"893_CR22","unstructured":"The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group, Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J. 2022;43:1104\u201320."},{"key":"893_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13098-020-00586-4","volume":"12","author":"B de Almeida-Pititto","year":"2020","unstructured":"de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12:75.","journal-title":"Diabetol Metab Syndr"},{"key":"893_CR24","doi-asserted-by":"publisher","first-page":"e0241824","DOI":"10.1371\/journal.pone.0241824","volume":"15","author":"FK Ho","year":"2020","unstructured":"Ho FK, Petermann-Rocha F, Gray SR, Jani BD, Katikireddi SV, Niedzwiedz CL, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One. 2020;15:e0241824.","journal-title":"PLoS One"},{"key":"893_CR25","doi-asserted-by":"publisher","first-page":"100108","DOI":"10.1016\/j.lanwpc.2021.100108","volume":"9","author":"H Surendra","year":"2021","unstructured":"Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Health West Pac. 2021;9:100108.","journal-title":"Lancet Reg Health West Pac"},{"key":"893_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","volume":"43","author":"Y Matsuzawa","year":"2020","unstructured":"Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257\u201366.","journal-title":"Hypertens Res"},{"key":"893_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40885-021-00168-0","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang SH, Lee DH, Han KD, Jung JH, Park SH, Dai AM, et al. Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19. Clin Hypertens. 2021;27:11.","journal-title":"Clin Hypertens"},{"key":"893_CR28","doi-asserted-by":"publisher","first-page":"699984","DOI":"10.3389\/fmed.2021.699984","volume":"8","author":"H Ma","year":"2021","unstructured":"Ma H, Ye Q, Ding W, Jiang Y, Wang M, Niu Z, et al. Can Clinical Symptoms and Laboratory Results Predict CT Abnormality? Initial Findings Using Novel Machine Learning Techniques in Children With COVID-19 Infections. Front Med (Lausanne). 2021;8:699984.","journal-title":"Front Med (Lausanne)"},{"key":"893_CR29","doi-asserted-by":"crossref","unstructured":"Fresan U, Guevara M, Trobajo-Sanmartin C, Burgui C, Ezpeleta C, Castilla J Hypertension and related comorbidities as potential risk factors for covid-19 hospitalization and severity: a prospective population-based cohort study. J Clin Med. 2021;10:1194.","DOI":"10.3390\/jcm10061194"},{"key":"893_CR30","doi-asserted-by":"publisher","first-page":"e0248058","DOI":"10.1371\/journal.pone.0248058","volume":"16","author":"J Park","year":"2021","unstructured":"Park J, Lee SH, You SC, Kim J, Yang K. Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea. PLoS One. 2021;16:e0248058.","journal-title":"PLoS One"},{"key":"893_CR31","doi-asserted-by":"crossref","unstructured":"Rezel-Potts E, Douiri A, Chowienczyk PJ, Gulliford MC Antihypertensive medications and COVID-19 diagnosis and mortality: population-based case-control analysis in the United Kingdom. Br J Clin Pharmacol. 2021;87:4598\u2013607.","DOI":"10.1111\/bcp.14873"},{"key":"893_CR32","doi-asserted-by":"publisher","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","volume":"4","author":"R Baral","year":"2021","unstructured":"Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e213594.","journal-title":"JAMA Netw Open"},{"key":"893_CR33","doi-asserted-by":"crossref","unstructured":"Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, et al. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. Open Heart. 2020;7:e001353.","DOI":"10.1136\/openhrt-2020-001353"},{"key":"893_CR34","unstructured":"Group ICC. Symptoms at presentation for patients admitted to hospital with Covid-19: results from the ISARIC prospective multinational observational study. medRxiv. 2020;10:20219519."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00893-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T07:09:06Z","timestamp":1657868946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00893-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00893-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BW has received honoraria for lectures on hypertension at medical\/scientific meetings supported by Daiichi Sankyo, Pfizer, Menarini, Novartis, Boehringer Ingelheim, Servier. All other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}